The receptor tyrosine kinase family of the epidermal growth factor, which also includes HER2/neu (ErbB2), ErbB3 (HER3), and ErbB4 (HER4), includes the epidermal growth factor receptor (EGFR; ErbB1). The extracellular ligand-binding ectodomain, the single chain transmembrane domain, and the intracellular tyrosine kinase domain make up the EGFR, which is located at the cell surface. Epidermal growth factor (EGF), transforming growth factor (TGF-), amphiregulin, heparin-binding EGF, and betacellulin are just a few of the ligands that bind to and activate the EGFR.
The tyrosine kinase domain is activated by the receptors' formation of homo- or heterodimeric complexes after ligand binding. The Ras-Raf-MAP kinase, PI-3K/Akt, PKC, and Stat/Jak signaling pathways are all activated as a result of the dimerization and autophosphorylation of EGFR. The EGFR is activated to control cellular survival, differentiation, and proliferation. The EGFR has been derided as a proto-oncogene primarily because of its function in encouraging cell proliferation and preventing apoptosis.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69393 | ErbB-2-binding peptide (HER2-binding peptide) | 562791-56-4 | ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. |
|
V3252 | Erlotinib mesylate | 248594-19-6 | Erlotinib mesylate (also known as OSI-744 mesylate, trade name:Tarceva) is the mesylate salt of erlotinib which is an EGFR (epidermal growth factor receptor) inhibitor with IC50 of 2 nM in cell-free assays, and is >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
|
V69338 | Fidasimtamab (IBI-315; BH2950) | 2377419-89-9 | Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that can simultaneously target, bind and inhibit HER2 and PD-1 and their downstream signaling pathways, and connect PD-1-expressing T cells to HER2-expressing T cells. |
|
V4254 | FIIN-3 | 1637735-84-2 | FIIN-3 is a novel, potent, selective, irreversible and the next-generation covalent FGFR inhibitor with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
|
V69362 | Futuximab | 1310460-85-5 | Futuximab is a chimeric monoclonal antibody (mAb) that targets non-overlapping epitopes on EGFR. |
|
V69440 | Gancotamab (MM-302) | 1509928-00-0 | Gancotamab (MM-302) is a HER2-targeting antibody-liposomal doxorubicin conjugate with anti-tumor activity. |
|
V3289 | Gefitinib hydrochloride | 184475-55-6 | Gefitinib hydrochloride, the HCl salt of Gefitinib (formerly also known as ZD1839 or trade name: Iressa), is a potent and orally-bioavailable EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
|
V69384 | Gefitinib impurity 2 (gefitinib impurity 1) | 246512-44-7 | Gefitinib impurity 2 is an impurity in Gefitinib. |
|
V79570 | Gefitinib N-oxide hydrochloride | Gefitinib N-oxide HCl is the N-oxide analogue of Gefitinib. | |
|
V69442 | HER2-IN-12 | 2820126-51-8 | HER2-IN-12 is a HER2 inhibitor (IC50= 121 nM). |
|
V69429 | HER2-IN-13 | 2414056-34-9 | HER2-IN-13 (Compound 33) is a HER2 inhibitor (antagonist) with IC50 of 8 nM. |
|
V69419 | HER2-IN-14 | 2414056-35-0 | HER2-IN-14 (Compound 34) is a HER2 inhibitor (antagonist) with IC50 of 18 nM. |
|
V69425 | HX103 | 2566466-98-4 | HX103 is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorescent probe. |
|
V69358 | Imgatuzumab (RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody) | 959963-46-3 | Imgatuzumab (RG 7160) is a humanized monoclonal antibody (mAb) directed against EGFR. |
|
V76892 | Inetetamab | Inetetamab is a monoclonal antibody (mAb) that binds to HER2 receptor domain IV. | |
|
V69351 | Intetumumab (CNTO 95; Anti-Human CD51 Recombinant Antibody) | 725735-28-4 | Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody (mAb) that is glycoengineered to enhance antibody-dependent cellular cytotoxic effect (ADCC). |
|
V69807 | Isoprocurcumenol | 102130-90-5 | Isoprocurcumenol is a guaiac-type sesquiterpene extracted from Curcuma comosa. |
|
V69370 | Istiratumab (MM 141; MM-005) | 1509928-04-4 | Istiratumab (M-6495) is a bispecific monoclonal antibody (mAb) targeting IGF-1R and ErbB3. |
|
V69350 | Izalontamab (SI-B001) | 2559704-24-2 | Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody (mAb) with high selectivity for EGFR/HER3 heterodimers. |
|
V69412 | JBJ-02-112-05 | 2748162-29-8 | JBJ-02-112-05 is a potent, mutation-selective, allosteric and orally bioactive EGFR inhibitor (antagonist) with IC50 of 15 nM against EGFRL858R/T790M. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
